Milan's Aptadir Therapeutics Raises €40 Million Seed Round for RNA Drugs That Switch Silenced Genes Back On

Aptadir Therapeutics, a Milan-based biotechnology company, has raised €40 million, about $45 million, in a seed financing round led by 4BIO Capital to develop a new class of RNA medicines designed to switch back on genes that have been abnormally silenced.

Existing investor EXTEND, the initiative that backed Aptadir at the pre-seed stage, participated again, alongside CDP Venture Capital, Xgen Ventures, Indaco Bio, Angelini Ventures, Kerna Ventures, Italian Angels for Biotech and members of Club degli Investitori. The round was announced on 29 September 2026.

The size of the round is unusual. Seed financings in software rarely exceed a few million dollars, and even in biotechnology, a €40 million seed round stands out, particularly in Europe. It reflects investor conviction that Aptadir's scientific platform could open up an entirely new approach to treating genetic diseases and cancers.

The science of silenced genes

Every cell in the human body carries the same genetic code, yet different cells switch different genes on and off. One of the key mechanisms controlling this is DNA methylation, the addition of small chemical tags to DNA that can silence a gene without changing its sequence. Methylation is essential for normal development, but when it goes wrong, it can switch off genes that are needed for healthy function.

Abnormal methylation plays a role in a range of conditions. In some cancers, genes that normally suppress tumour growth are silenced. In certain genetic disorders, a gene that is structurally present cannot be used because it has been shut down by methylation.

Existing drugs that target DNA methylation, known as hypomethylating agents, act broadly across the genome. They are used in some blood cancers but can cause significant side effects because they affect many genes at once. The goal of Aptadir's approach is precision: to reverse methylation at a single gene, restoring its function without disrupting others.

DNMT-interacting RNAs

Aptadir's platform is built on DNMT-interacting RNAs, or DiRs, a novel class of RNA inhibitors that block the enzymes, called DNA methyltransferases, responsible for adding methylation tags at specific genes. By interfering with those enzymes only where they act on a particular gene, DiRs aim to reactivate that gene selectively.

The technology draws on research from several institutions: Beth Israel Deaconess Medical Center, part of Harvard Medical School; Italy's National Research Council; the Cancer Science Institute of Singapore; and City of Hope National Medical Center in California. Scientists involved in the work include Annalisa Di Ruscio and Daniel Tenen of Beth Israel Deaconess, Vittorio de Franciscis of the National Research Council and Marcin Kortylewski of City of Hope. The company is led by chief executive Giovanni Amabile.

Fragile X first

Aptadir's lead programme, CAP1-FMR1, targets Fragile X syndrome, the most common inherited cause of intellectual disability and a leading single-gene cause of autism. The condition is caused by the silencing of the FMR1 gene, which leads to reduced or absent production of a protein needed for normal brain development. In most cases, the gene is silenced through an expansion of a repeated DNA sequence that triggers methylation.

There is currently no approved treatment that addresses the underlying cause of Fragile X syndrome. Existing care focuses on managing symptoms through educational support, behavioural therapy and medications for associated conditions such as anxiety and attention difficulties. A drug that could reactivate FMR1 would represent a fundamentally different approach.

Aptadir says its approach has restored gene expression in patient-derived disease models. That evidence remains preclinical, and the company will need to demonstrate safety and efficacy in human studies, a process that typically takes years. Delivering RNA medicines to the brain is a particular challenge, and the company will need to show that its molecules can reach target cells in sufficient quantities.

The company also plans to develop treatments for intractable cancers and other genetic conditions, including myelodysplastic syndrome, a group of blood disorders in which abnormal methylation is known to play a role.

Why investors are paying up

The scale of the seed round reflects the economics of drug development. Moving a therapeutic from laboratory discovery towards clinical trials requires manufacturing development, toxicology studies, regulatory preparation and specialised staff, all before any revenue can be generated. Investors backing Aptadir are financing the company through that expensive transition.

The attraction is platform potential. If DiRs can selectively reactivate one silenced gene, the same mechanism could, in principle, generate candidates against many diseases where methylation plays a role. That makes the company a bet on a new therapeutic modality rather than a single product, the kind of opportunity that can justify large early cheques if the science holds.
## Epigenetic medicine comes of age

Aptadir is part of a wider wave of interest in epigenetic therapies, which aim to change how genes are expressed rather than altering the underlying DNA sequence. Advances in genome sequencing, RNA chemistry and delivery technologies have made it possible to target gene regulation with increasing precision, and several companies worldwide are developing tools to switch genes on or off at specific locations.

The appeal of such approaches lies partly in their potential safety profile. Because they do not permanently alter the genome, epigenetic therapies may avoid some of the risks associated with gene editing, such as unintended changes to DNA. They could also, in principle, be dosed and adjusted over time. At the same time, the durability of their effects and the reliability of delivery to target tissues remain open questions that only clinical studies can answer.

A boost for European biotech

The financing is also significant for Italy's life sciences ecosystem. Italian research institutions have produced strong science, but the country has historically lagged behind the United Kingdom, Germany, France and the Nordic countries in converting that science into venture-backed companies. The participation of CDP Venture Capital, backed by the Italian state, and a network of domestic angel investors alongside a specialist international lead investor points to a maturing ecosystem.

For patients and families affected by Fragile X syndrome and other conditions caused by silenced genes, Aptadir's progress will be followed with hope and caution. Many promising preclinical approaches fail in human trials, and the path to an approved medicine is long. Still, a well-funded company pursuing a genuinely new mechanism adds a meaningful option to a field where few exist.

The next milestones will be the selection of clinical candidates, completion of preclinical safety studies and the start of first-in-human trials. If Aptadir can show that its RNA molecules safely restore gene function in people, it could pioneer a new chapter in epigenetic medicine, one that treats disease not by changing the genetic code, but by reminding cells how to read it.